LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

LLY

754.57

-0.24%↓

JNJ

178.08

-0.17%↓

ABBV

218.3

-0.8%↓

UNH

352.9

-0.29%↓

AZN

79.54

-1.96%↓

Search

Zai Lab Ltd ADR

Suletud

SektorTervishoid

32.73 0.74

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

32.42

Max

32.87

Põhinäitajad

By Trading Economics

Sissetulek

7.7M

-41M

Müük

3.5M

110M

Kasumimarginaal

-37.032

Töötajad

1,869

EBITDA

1.4M

-55M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+63.84% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. nov 2025

Turustatistika

By TradingEconomics

Turukapital

-588M

3.6B

Eelmine avamishind

31.99

Eelmine sulgemishind

32.73

Uudiste sentiment

By Acuity

100%

0%

356 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

Zai Lab Ltd ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. sept 2025, 22:41 UTC

Suurimad hinnamuutused turgudel

GlucoTrack Stock Falls on Plans to Sell $3 Million Note

12. sept 2025, 16:04 UTC

Suurimad hinnamuutused turgudel

Upexi Shares Climb on Solana Gains

14. sept 2025, 23:48 UTC

Market Talk

Oil Futures Mixed Amid Divergent Signals -- Market Talk

14. sept 2025, 23:41 UTC

Market Talk

Gold Edges Lower on Likely Technical Correction -- Market Talk

14. sept 2025, 23:38 UTC

Market Talk

China's Economic Activity Data May Continue Reflecting Slowdown -- Market Talk

14. sept 2025, 23:13 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

14. sept 2025, 23:13 UTC

Market Talk

Global Energy Roundup: Market Talk

14. sept 2025, 23:13 UTC

Market Talk

Infratil May Need to Be More Aggressive With Asset Sales -- Market Talk

14. sept 2025, 23:13 UTC

Market Talk

Global Equities Roundup: Market Talk

14. sept 2025, 23:04 UTC

Market Talk

Aristocrat's Interactive Unit Appears in Safe Hands -- Market Talk

13. sept 2025, 08:20 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

12. sept 2025, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

12. sept 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. sept 2025, 20:09 UTC

Tulu

Correction to Opendoor Is Sliding. Don't Call It a Meme Stock, Says New Chairman. -- Barrons.com

12. sept 2025, 19:23 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. sept 2025, 19:16 UTC

Market Talk

Oil Futures End Volatile Week With Moderate Gains -- Market Talk

12. sept 2025, 19:03 UTC

Market Talk

Natural Gas Futures Held Back By Plump Inventories -- Market Talk

12. sept 2025, 18:59 UTC

Market Talk

Dollar Pares Gains as Economy Keeps Showing Signs of Cooling -- Market Talk

12. sept 2025, 18:38 UTC

Market Talk
Tulu

Adobe Seen Reaching Turning Point in AI Cycle -- Market Talk

12. sept 2025, 18:33 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 416 -- Market Talk

12. sept 2025, 18:22 UTC

Market Talk

Canada's Divergence With US On Capex Spending is 'Appalling' -- Market Talk

12. sept 2025, 16:56 UTC

Market Talk

Renewable Fuels Association Calls for Nationwide E15 Following WASDE -- Market Talk

12. sept 2025, 16:22 UTC

Tulu

Adobe Earnings Were 'Solid.' Long-Term Growth Concerns Remain. -- Barrons.com

12. sept 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. sept 2025, 16:19 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

12. sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

12. sept 2025, 16:11 UTC

Tulu

Novartis Catches a 'Sell.' Goldman Sachs Says the Stock Is Overvalued. -- Barrons.com

12. sept 2025, 15:37 UTC

Market Talk

Gold Holds Near All-Time Highs Ahead of Fed Meeting Next Week -- Market Talk

12. sept 2025, 15:22 UTC

Market Talk

European Gas Lifted by Geopolitical Risks But Storage Levels Ease Supply Fears -- Market Talk

12. sept 2025, 15:07 UTC

Omandamised, ülevõtmised, äriostud

These Stocks Are Moving the Most Today: Warner Bros., Paramount Skydance, Tesla, Super Micro, Microsoft, Figure Technology, and More -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

Zai Lab Ltd ADR Prognoos

Hinnasiht

By TipRanks

63.84% tõus

12 kuu keskmine prognoos

Keskmine 53.74 USD  63.84%

Kõrge 69 USD

Madal 39 USD

Põhineb 8 Wall Streeti analüütiku instrumendi Zai Lab Ltd ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

8 ratings

7

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

28.13 / 31.12Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Keskpikk perspektiiv

Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Zai Lab Ltd ADR

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT; and strategic collaboration with Pfizer for XACDURO. The company was incorporated in 2013 and is headquartered in Shanghai, China.
help-icon Live chat